<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Novartis AG | Company News & Executive Profiles - NVS | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/novartis+ag.html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Novartis AG]]></description>
	<s:counts start="0" returned="10" found="1043" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Can Novartis Win Race to Launch First Oral Drug for MS?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005592/can-novartis-win-race-to-launch-first-ms-oral-drug/]]></link>
		<description><![CDATA[Novartis AG is jockeying with German drug maker Merck KgaA to deliver the first disease-modifying treatment for relapsing forms of multiple sclerosis that can be taken orally, rather than by infusion or injection. Fingolimod could finally move ahead in the race to market, as the FDA rejected Merck's new drug...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 03 Dec 2009 10:25:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/tablets.html"><![CDATA[Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks.html"><![CDATA[Notebooks]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[Hardware]]></category>
		<category domain="http://resources.bnet.com/topic/notebooks+%2526+tablets.html"><![CDATA[Notebooks & Tablets]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">MRK,MSFT,NVS</category>
	</item>
	<item>
		<title><![CDATA[Merck KGaA: Another Stumble Leaves Investors Worried]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175962-merck-kgaa-another-stumble-leaves-investors-worried%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: It was the kind of news that Merck KGaA (MKGAY.PK) could have done without following its failure last week to get European approval for Erbitux in lung cancer.  As such, the bombshell that the FDA had issued a refuse to file letter in response to the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 01 Dec 2009 09:08:22 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Incyte's Collaboration with Novartis AG Presents Great Opportunity]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175906-incyte-s-collaboration-with-novartis-ag-presents-great-opportunity%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Incyte Corporation INCY entered into a collaboration and license agreement with Novartis AG NVS regarding two of its pipeline candidates &#8211; INCB18424, an oral JAK1/JAK2 inhibitor and INCB28060, an oral cMET inhibitor. While the former is currently being studied in a phase III clinical trial for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 01 Dec 2009 05:45:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/incyte+corp..html"><![CDATA[Incyte Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">INCY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">INCY,NVS</category>
	</item>
	<item>
		<title><![CDATA[Can Novartis JAK Up Incyte's Profitability?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005537/can-novartis-jak-up-incytes-profitability/]]></link>
		<description><![CDATA[Paul Friedman, chief executive of Incyte, believes that a newly-inked collaborative and licensing deal with Novartis for INCB18424, an oral JAK1/JAK2 inhibitor entering late-stage development for the blood disorder myelofibrosis, could drive the company to first-time profitability. Although early clinical evidence suggests that regulating cell signaling through this cytokine pathway...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 30 Nov 2009 10:52:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Novartis Partners with U.S. Government for Faster Flu Vaccine Manufacturing]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175396-novartis-partners-with-u-s-government-for-faster-flu-vaccine-manufacturing%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  Novartis NVS and the U.S. Department of Health and Human Services will invest nearly $1 billion to build the first large cell culture-based flu vaccine manufacturing center in the United States. The new North Carolina manufacturing facility will be capable of producing up to 150...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 26 Nov 2009 12:34:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Novartis Looks at Combination Pills to Fix Hypertension Franchise]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005479/novartis-looks-to-combination-pills-to-fix-hypertension-franchise/]]></link>
		<description><![CDATA[Novartis could find its leadership position in blood pressure therapies challenged in the next two years, owing to generic intrusion on its flagship anti-hypertensive drug Diovan. Near-term, with no novel agents emerging from its  drug pipeline, the drugmaker is reaching into its life cycle management playbook and introducing a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 24 Nov 2009 10:44:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/leadership.html"><![CDATA[Leadership]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Titan Pharmaceuticals: Finally Reaching Its Potential]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173912-titan-pharmaceuticals-finally-reaching-its-potential%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  It was a quick rise to the $2.40 level for shares of Titan Pharmaceuticals (TTNP.PK), as it finally looks like the stock is starting to trade towards its potential. With the heavyweight Novartis NVS set to commercially launch Fanapt early next year, the schizophrenia drug could quickly...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 17 Nov 2009 02:02:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Novartis Sought Ban on Bunny Costumes at Protests]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005333/novartis-sought-ban-on-bunny-costumes-at-protests/]]></link>
		<description><![CDATA[Novartis NVS lost a ruling in a British court in which it asked for a ban on animal rights protestors wearing animal costumes that cover their faces. The company sought an injunction against protesters against Huntingdon Life Sciences LSR, an animal testing lab that is at the heart of a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 16 Nov 2009 15:28:08 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/animal.html"><![CDATA[Animal]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Novartis Says Weak IP Protection Makes India R&D Impossible]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173179-novartis-says-weak-ip-protection-makes-india-r-d-impossible%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Novartis (NYSE: NVS) once again said that India is not a place to do R&D because its IP laws are not strong enough to protect discoveries. In 2006, Novartis made a commitment to build a $125 million R&D facility in Hyderabad. The next year, after the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 13 Nov 2009 02:40:05 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Novartis Gives Thumbs Down To R&D In India]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/novartis-thumbs-india/20109/]]></link>
		<description><![CDATA[Frustrated with patent challenges, Novartis has put its R&D activities in India on the back burner, The Economic Times reports. Chief executive Dan Vasella, who was in Mumbai to attend a Pepsico board meeting, tells the paper that intellectual property protection in India is not what it ought to be....]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 12 Nov 2009 07:47:56 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
</channel>
</rss>
